Who is sponsoring NCT05257967?

NCT05257967 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT05257967?

Interventions in NCT05257967: Lumbar puncture and Phlebotomy.

What condition does NCT05257967 study?

NCT05257967 studies EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer.

Is NCT05257967 still recruiting?

NCT05257967 is currently recruiting now. Last updated 11 February 2025.

Last reviewed 2025-02-11 · How we verify

NCT05257967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

Recruiting now NA Last updated 11 February 2025

What this trial tests

NA trial testing Lumbar puncture and Phlebotomy in EGFR Activating Mutation in 10 participants. Currently enrolling.

Timeline

18 July 2022

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	10
Start date	18 July 2022
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	1 location across Canada

Drugs / interventions tested

Lumbar puncture and Phlebotomy

Conditions studied

EGFR Activating Mutation — all drugs for EGFR Activating Mutation →
Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →
Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

British Columbia Cancer Agency

Who can join

18 and older, any sex, with EGFR Activating Mutation or Leptomeningeal Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC. Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer.
Desai A, Vázquez TA, Arce KM, Corassa M, et al · · 2024 · cited 22× · PMID 38473302 · DOI 10.3390/cancers16050940
Advancing leptomeningeal metastases treatment in <i>EGFR</i>-mutated non-small cell lung cancer: lessons from the BLOSSOM trial.
Bortolot M, Huijs JWJ, Brandsma D, Compter A, et al · · 2025 · cited 1× · PMID 39958217 · DOI 10.21037/tlcr-24-1006
Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer.
Dhillon P, Du S, Cheng H. · · 2025 · PMID 41154383 · DOI 10.3390/cancers17203327

Verify or expand the search:

Other recruiting trials for EGFR Activating Mutation

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
NCT06685718 — A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer · Phase 1 · active not recruiting
NCT06363734 — Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT05948813 — TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases · Phase 2 · recruiting
NCT05768490 — Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastas · Phase 3 · recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05257967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 11 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05257967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing